Bristol Myers Squibb and BioNTech to co-develop cancer immunotherapy BNT327 in a deal worth up to $11.1 billion.

Bristol-Myers Squibb was founded in 1858 and has grown ... Around the same time, the prototype of the Squibb logo was designed. The logo represented product uniformity, purity, efficacy and ...

U.S.-listed shares of BioNTech jumped more than 15% Monday morning after the German vaccine maker announced a collaboration ...

Bristol-Myers Squibb's financial position improved, it raised both its EPS guidance and revenue expectations, and Opdivo's ...